Equity Overview
Price & Market Data
Price: $0.904
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $3,436,122
Volume: 0
Performance Metrics
1 Week: -3.81%
1 Month: -12.21%
3 Months: -1.73%
6 Months: -21.37%
1 Year: -62.17%
YTD: -19.95%
Company Details
Employees: 17
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Canada
Details
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy. It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance. The company is based in Calgary, Canada.